The fine and specialty chemicals business: how it really works: Key terms, quiz and sources

Understanding Chemicals / Module 12: The fine and specialty chemicals business: how it really works Wrap-up

The fine and specialty chemicals business: how it really works: review

Key terms

Commodity chemical: A large-volume, low-price, standardised chemical made in dedicated plants and sold on specification for many uses, such as methanol.
Fine chemical: A complex, single, pure substance made in limited volumes in multipurpose plants and sold on specification to other chemical or life science companies, usually above about $10/kg.
Specialty chemical: A formulated product containing one or more active ingredients and sold on its performance, usually under a brand name.
Active pharmaceutical ingredient (API): The drug substance that produces a medicine's effect; a fine chemical before it is formulated into the drug product.
Advanced intermediate: One of the last compounds before the API in a synthesis, usually made under cGMP and often custom-made for one customer.
cGMP: Current Good Manufacturing Practice: regulations, set in the US by the FDA, that govern how drug substances and advanced intermediates are made, documented and tested.
Drug master file (DMF): A dossier filed once with the FDA by an API maker that can support approval of any generic drug using that API.
Multipurpose plant: A batch plant of standard reactors, filters and dryers that makes many different products in turn by reconfiguring equipment between campaigns.
Campaign: A run of consecutive batches of one product in a multipurpose plant, followed by cleaning and changeover to the next product.
Nutsche: A large filter vessel, often agitated and heated or cooled, used to separate, wash and sometimes dry crystals from the liquid they formed in.
Volume-time-output (VTO): Reactor volume occupied multiplied by hours, divided by kilograms of good product; the basis of conversion cost in a multipurpose plant.
Overall Equipment Effectiveness (OEE): Availability times performance times quality: the share of a plant's theoretical capacity that turns into good product.
Custom manufacturing: Exclusive production of a customer's proprietary compound, usually an advanced intermediate, from scale-up to commercial supply under a supply agreement.
Toll manufacturing: Conversion of a customer's own starting materials by a customer-supplied process, for a fee per unit of output.
API-for-generics: Off-patent drug substances developed and sold by a fine chemical company to many generic drug makers at market prices.
Contract research organisation (CRO): A firm selling research services, such as route development and samples, usually billed per full-time-equivalent scientist-year.
Technology package: The customer's transfer document for a custom manufacturing project: reaction scheme, specifications, quantities, analytical methods and safety notes.
Enantiomer: One of two mirror-image forms of a chiral molecule; often only one form is the effective drug.
E-factor: Kilograms of waste generated per kilogram of product; typically 5-50 for fine chemicals.

Try it in the table

Open the Custom synthesis (CDMO) tile and compare what it says about contract terms and customers with Pollak's shift from five-year take-or-pay contracts to one-year spot orders. Which era does today's market look like?
Open the Methanol and Acetic acid tiles, then Small-molecule APIs. Note the price per kilogram on each and check that the jump matches the roughly 10,000-fold rise from methanol to atorvastatin in Pollak's value chain.
Open the Paracetamol tile. Pollak lists paracetamol as a two-step synthesis made at more than 10,000 tonnes a year below $10/kg. Decide whether it behaves more like a commodity or a fine chemical, and look at where most of it is now made.
Open Pharma starting materials and intermediates and look for how much of supply comes from China and India. Compare it with Pollak's 2008 shares: Asia about 55% of merchant API-for-generics.
Open the Herbicides and Insecticides tiles and compare a large-volume old active with a modern low-dose one. Use Pollak's prices (2,4-D about $6/kg, imidacloprid about $500/kg) to explain why modern actives suit multipurpose plants.
Open Chiral and specialty building blocks and Industrial enzymes. Find an example where an enzyme replaced a chemical step and estimate the yield gain using the 50% ceiling of a classical resolution.

Final quiz

Which combination best describes a fine chemical in Pollak's definition?

Fine chemicals are single, pure, complex substances made in limited volumes in multipurpose plants and sold on specification at higher prices; mixtures sold on performance are specialties.

Pollak's indicative atorvastatin API value is $2,000/kg and 400 t a year. Against $11.4 billion of Lipitor sales, the API value is roughly:

400,000 kg x $2,000 = $800 million; $0.8 billion / $11.4 billion = about 7%. The API is a small part of a patented drug's price.

A multipurpose plant has $20 million of yearly operating cost, 7,920 hours, 100 m3 of reactors and 60% utilisation. What is its standard cost per m3-hour?

Available capacity is 7,920 x 100 x 0.6 = 475,200 m3-hours; $20 million / 475,200 = $42.09.

Which reason does Pollak NOT give for keeping reactors in multipurpose plants at a few cubic metres?

There is no cGMP size limit. The limits are economic and practical: campaign length, working capital, heat transfer time, batch value and building or utility constraints.

At which point in a drug's life does Pollak see the most attractive entry for an established custom manufacturer?

At Phase II/III the chance of launch becomes real, the route is frozen and the customer decides whether to outsource, usually to approved suppliers.

A generic API's market price is $40/kg. The supplier needs a 10% margin, has conversion cost of $20/kg and raw materials of $18/kg. Under top-down pricing:

Top-down starts from the market price: $40 - $4 margin - $20 conversion - $18 raw materials = -$2. Pollak says either costs must be cut or the business is not viable.

Why did Italy and Spain become strongholds of API-for-generics?

Late product-patent laws let Italian and Spanish firms build experience making molecules still patented elsewhere; India and China followed the same path until 2005.

Which of these is one of Pollak's three key indicators of a fine chemical company fit for the future?

Pollak names Asian presence, ownership and size (ideally family-owned, $100-250 million) and differentiating technologies. He doubts one-stop shops, and Divi's shows that reactor volume alone does not create sales.

Next module: Biorefineries and platform chemicals →

Sources for this module

Pollak, P. (2011). Fine Chemicals: The Industry and the Business, 2nd ed. Wiley, Hoboken. · pdf pp. 25-108 (Part I), 116-198 (Part II), 201-255 (Part III), 269-272 (Appendices A.3, A.4)
Kent, J.A. (ed.) (2012). Handbook of Industrial Chemistry and Biotechnology, 12th ed. Springer. Ch 1 (Aftalion), Recent History of the Chemical Industry · pdf pp. 29-30
Kent (2012), Ch 10 (Barnicki), Synthetic Organic Chemicals · pdf pp. 318-319
Kent (2012), Ch 11 (Kadow et al.), Chemistry in the Pharmaceutical Industry · pdf pp. 401-406, 425-427
Wittcoff, H.A., Reuben, B.G. & Plotkin, J.S. (2004). Industrial Organic Chemicals, 2nd ed. Wiley. Ch 1, The Chemical Industry · pdf pp. 46, 59, 67-68, 78
Cefic (2025). Facts and Figures of the European Chemical Industry 2025, data file · Sales, R&D Spending, Extra-EU27 Exports and Extra-EU27 Imports sheets